

A\$70m capital raising & Lantheus investment approved at EGM

Sydney, Australia – 14 August 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that all resolutions at today’s Extraordinary General Meeting (EGM) were carried on a poll.

This includes approval of the remaining components of the A\$70 million capital raising announced on 25 June 2024, including a A\$7.5 million investment at \$0.05 per share by leading radiopharmaceutical-focused NASDAQ-listed company Lantheus Holdings (NSDQ: LNTX).

Radiopharm’s CEO & MD, Riccardo Canevari said, “The capital raising and strategic investment by Lantheus, one of the world’s largest pure-play radiopharmaceutical companies, is a strong endorsement of the potential within RAD. This confidence in our assets and commitment to our future pipeline speaks volumes, and this has been further backed by specialist biotechnology institutional investors in the US, Australia and elsewhere. As we move forward, this not only solidifies our growth trajectory but also strengthens our position in the global market.”

The Lantheus investment forms part of a total package previously announced to the market on 20 June 2024 which also includes:

- Potential further investment of up to US\$5.0 million (A\$7.5 million) via options with a six-month term exercisable at \$0.05 per share;
- The US\$2.0 million (A\$3.0 million) preclinical assets transfer and development agreement, of which receipt was announced to the ASX on 5 August 2024.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

**ASX ANNOUNCEMENT
14 AUGUST 2024**



Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

InvestorHub – <https://investorhub.radiopharmtheranostics.com/>